Bin Wu

Bin Wu

Auto-generated profile, based on publicly available information

Bin Wu

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
XOXiaomin Ou
Xiaomin Ou
RZRuiping Zhai
Ruiping Zhai
WWWenjun Wei
Wenjun Wei
JCJiaying Chen
Jiaying Chen
DODan Ou
Dan Ou
YWYu Wang
Yu Wang
Purpose: The aim of this study was to assess the efficacy, toxicities, and potential role of larynx preservation of induction chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitor in locally advanced laryngeal and hypopharyngeal cancer.Patients and Methods: This is a single-arm phase II study. Patients with histopathologically confirmed, resectable locally advanced laryngeal/hypopharyngeal squamous cell carcinoma and Eastern Cooperative Oncology Group Performance Status 0–1 were eligible. Three cycles of induction chemotherapy (paclitaxel 175 mg/m2 d1, cisplatin 25 mg/m2 d1–3) combined with PD-1 inhibitor (toripalimab 240 mg d0) were administered. Response assessment was performed after induction chemoimmunotherapy using RECIST 1.1 criteria. Patients with a complete/partial response of the primary tumor received concurrent chemoradiation, followed by maintenance therapy of toripalimab. Otherwise, patients were referred to surgery, followed by adjuvant (chemo) radiation and maintenance therapy of toripalimab. The primary endpoint is a larynx preservation rate at 3 months postradiation.Results: Twenty-seven patients were enrolled. Most cases exhibited stage IV disease (81.5%), with T4 representing 37.0%. Five patients underwent pretreatment tracheostomy because of impaired larynx function. Overall response rate of induction chemoimmunotherapy was 85.2%. At 3 months postradiation, the larynx preservation rate was 88.9%. With a median follow-up of 18.7 months, the 1-year overall survival rate, progression-free survival rate, and larynx preservation rate were 84.7%, 77.6%, and 88.7%, respectively. When excluding those with pretreatment tracheostomy, the 1-year larynx preservation rate was 95.5%. Exploratory analysis revealed that relapse correlated with enrichment of RNA signature of hypoxia and M2 macrophage–associated genes.Conclusions: Induction toripalimab combined with chemotherapy provided encouraging activity, promising larynx preservation rate and acceptable toxicity in this cohort of extensively locally advanced laryngeal and hypopharyngeal cancer.

1 April 2023 in Quantitative Imaging in Medicine and Surgery
Verified
Journal Article
Open access
PDF file
QLQiao Li
Qiao Li
TXTingting Xu
Tingting Xu
JGJing Gong
Jing Gong
SXShiyu Xiang
Shiyu Xiang
CSChunying Shen
Chunying Shen
XLXueguan Lu
Xueguan Lu
Background: Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) is currently rising in incidence; however, a noninvasive approach to predicting HPV status that strongly correlates with p16 expression is lacking. This study aimed to develop a radiomics model based on multisequence magnetic resonance imaging (MRI) of primary tumor (PT) and lymph node (LN)-fused imaging features for the prediction of p16 status in OPSCC. Methods: In this retrospective study, 141 patients (comprising 116 patients in the training cohort and 25 patients in the testing cohort) with histopathologically confirmed (OPSCC) were enrolled consecutively from Fudan University Shanghai Cancer Center and Shanghai Ninth People’s Hospital between January 2011 and December 2020. HPV status was determined by p16 immunohistochemistry analysis. A total of 2092 radiomics features were initially computed and extracted from the 3D-segmented PT and largest LN based on contrast-enhanced T1-weighted imaging (CE-T1WI) and T2-weighted imaging (T2WI). A support vector machine classifier was employed to build the machine learning–based classification models dependent on p16 status. The models were validated in the testing cohort. The area under the receiver operating characteristic curve (AUC) was computed to assess the performance of each model. This diagnostic study was not registered on the clinical trial platform. Results: In the testing cohort, fusion models yielded better performance (AUC) compared with models based on a sole PT/LN [CE-T1WI: 0.80 (95% CI: 0.55–0.94) vs. 0.71 (95% CI: 0.47–0.88)/0.73 (95% CI: 0.48–0.90); T2WI: 0.74 (95% CI: 0.51–0.95) vs. 0.64 (95% CI: 0.38–0.85)/0.71 (95% CI: 0.48–0.88)]. Models based on multisequence imaging outperformed single CE-T1WI/T2WI models [PT: 0.74 (95% CI: 0.46–0.91) vs. 0.71 (95% CI: 0.47–0.88)/0.64 (95% CI: 0.38–0.85); LN: 0.78 (95% CI: 0.55–0.75) vs. 0.73 (95% CI: 0.48–0.90)/0.71 (95% CI: 0.48–0.88)]. Finally, the PT-LN fusion model based on multisequencing yielded the best classification performance with the highest AUC value of 0.91 (95% CI: 0.72–0.98) for the prediction of p16 expression. The differences between the performance of the final model and the other 8 models were significant (all P values <0.05). Conclusions: The results demonstrated that (I) the PT-LN fusion radiomics models improved the classification performance of the sole use of PT or LN for the prediction of p16 status, (II) the radiomics models based on multisequences outperformed the single-sequence models in the prediction of p16 status, and (III) the PT-LN fusion model based on multisequence MRI radiomics features could serve as a noninvasive method for acquiring the molecular information of patients with OPSCC, potentially assisting oncologists with their clinical decision-making.

6 August 2024 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
JJJianyun Jiang
Jianyun Jiang
BWBin Wu
Bin Wu
YSYing Sun
Ying Sun
JXJun Xiang
Jun Xiang
CSChunying Shen
Chunying Shen
ZXZuguang Xia
Zuguang Xia
Patients with recurrent or metastatic head and neck cancers (R/M HNCs) are prone to developing resistance after immunotherapy. This retrospective real-world study aims to investigate whether the addition of anlotinib can reverse resistance to PD-1 inhibitors (PD-1i) and evaluate the efficacy and safety of this combination in R/M HNCs. Main outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. Potential biomarkers included PD-L1 expression, lipid index, and genomic profiling. Twenty-one patients with R/M HNCs were included, including 11 nasopharyngeal carcinoma (NPC), five head and neck squamous cell carcinoma (HNSCC), three salivary gland cancers (SGC), and two nasal cavity or paranasal sinus cancers (NC/PNC). Among all patients, ORR was 47.6% (95% CI: 28.6–66.7), with 2 (9.5%) complete response; DCR was 100%. At the median follow-up of 17.1 months, the median PFS and OS were 14.3 months (95% CI: 5.9-NR) and 16.7 months (95% CI:8.4-NR), respectively. The median DOR was 11.2 months (95% CI: 10.1-NR). As per different diseases, the ORR was 45.5% for NPC, 60.0% for HNSCC, 66.7% for SGC, and 50.0% for NC/PNC. Most treatment-related adverse events (TRAEs) were grade 1 or 2 (88.9%). The most common grades 3–4 TRAE was hypertension (28.6%), and two treatment-related deaths occurred due to bleeding. Therefore, adding anlotinib to the original PD-1i could reverse PD-1 blockade resistance, with a favorable response rate, prolonged survival, and acceptable toxicity, indicating the potential as a second-line and subsequent therapy choice in R/M HNCs.

1 October 2018 in Medicine
Verified
Journal Article
Open access
ZZZhenwei Zhu
Zhenwei Zhu
PCPeng Cai
Peng Cai
JZJie Zhu
Jie Zhu
JCJianlei Chen
Jianlei Chen
BWBin Wu
Bin Wu
JWJian Wang
Jian Wang
Rationale: Hepatic hemangioma is the third most common pediatric tumor, and it is rare in the neonatal period. This case study presents a rare case of hepatic hemangioma found in a neonate. Patient concerns: A girl who was 18 days of age with the emergence of jaundice and an abdominal mass was admitted for physical examination in the local department. Diagnoses: An ultrasound showed that the hepatic left lobe was about 9 cm × 7 cm × 7 cm in size. A CT scan indicated a giant hemangioma in the hepatic left lobe. MRI detected a lesion measuring about 92 mm × 71 mm × 68 mm. Interventions: The patient was treated with propranolol 3.5 mg PO bid (body weight 3.8 kg) after 1 week of admission for 4 weeks, but the mass did not appear to regress. Surgery was then performed successfully. Outcomes: The patient recovered well without recurrence beyond one year. Lessons: Imaging strategies and prenatal diagnosis are vital for the diagnosis of infantile hepatic hemangioma. Propranolol is effective in both cutaneous and hepatic multifocal and diffuse hemangioma. Adequate treatment time is necessary to cure the disease. The role of propranolol in massive hepatic hemangioma remains uncertain and needs further investigation.

23 November 2018 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YCYanqiong Chen
Yanqiong Chen
BWBin Wu
Bin Wu
HLHui Liu
Hui Liu
DWDan Wang
Dan Wang
YGYajia Gu
Yajia Gu
This study aimed to investigate the diagnostic value of a dual-parametric 2D histogram classification method for breast lesions. This study included 116 patients with 72 malignant and 44 benign breast lesions who underwent CAIPIRINHA-Dixon-TWIST-VIBE dynamic contrast-enhanced (CDT-VIBE DCE) and readout-segmented diffusion-weighted magnetic resonance examination. The volume of interest (VOI), which encompassed the entire lesion, was segmented from the last phase of DCE images. For each VOI, a 1D histogram analysis (mean, median, 10th percentile, 90th percentile, kurtosis and skewness) was performed on apparent diffusion coefficient (ADC) and volume transfer constant (Ktrans) maps; a 2D histogram image (Ktrans-ADC) was generated from the pixelwise aligned maps, and its kurtosis and skewness were calculated. Each parameter was correlated with pathological results using the Mann–Whitney test and receiver operating characteristic curve analysis. For the Ktrans histogram, the area under the curve (AUC) of the mean, median, 90th percentile and kurtosis had statistically diagnostic values (mean: 0.760; median: 0.661; 90th percentile: 0.781; and kurtosis: 0.620). For the ADC histogram, the AUC of the mean, median, 10th percentile, skewness and kurtosis had statistically diagnostic values (mean: 0.661; median: 0.677; 10th percentile: 0.656; skewness: 0.664; and kurtosis: 0.620). For the 2D Ktrans-ADC histogram, the skewness and kurtosis had statistically higher diagnostic values (skewness: 0.831, kurtosis: 0.828) than those of the 1D histogram (all P < 0.05). The dual-parametric 2D histogram analysis revealed better diagnostic accuracy for breast lesions than single parametric histogram analysis of either Ktrans or ADC maps.

17 January 2024
Verified
Other
Open access
XOXiaomin Ou
Xiaomin Ou
RZRuiping Zhai
Ruiping Zhai
WWWenjun Wei
Wenjun Wei
JCJiaying Chen
Jiaying Chen
DODan Ou
Dan Ou
YWYu Wang
Yu Wang
Larynx preservation rate at three months post-radiotherapy according to T stage and pretreatment laryngeal function and baseline invasion (N=27)